Dogwood Therapeutics Inc., a development-stage biotechnology company, has announced the enrollment of the first 50 patients in its ongoing Phase 2b clinical trial for Halneuron®, a treatment for Chemotherapy-Induced Neuropathic Pain (CINP). The company remains on track to conduct an interim analysis of approximately 100 patients, with results anticipated in the fourth quarter of 2025. Halneuron® is being evaluated for its safety and efficacy against a placebo in cancer patients with neuropathy resulting from platinum or taxane-based chemotherapy regimens. The trial involves 8 once daily subcutaneous doses over 14 days, with a 28-day follow-up period. Primary endpoints include overall safety and changes in pain intensity, while secondary measures assess effects on sleep, fatigue, and overall health. Full results from the Phase 2b trial are expected in mid-2026.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。